Cargando…
Formulation approaches to pediatric oral drug delivery: benefits and limitations of current platforms
Introduction: Most conventional drug delivery systems are not acceptable for pediatric patients as they differ in their developmental status and dosing requirements from other subsets of the population. Technology platforms are required to aid the development of age-appropriate medicines to maximize...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Informa Healthcare
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4673516/ https://www.ncbi.nlm.nih.gov/pubmed/26165848 http://dx.doi.org/10.1517/17425247.2015.1060218 |
_version_ | 1782404754411880448 |
---|---|
author | Lopez, Felipe L Ernest, Terry B Tuleu, Catherine Gul, Mine Orlu |
author_facet | Lopez, Felipe L Ernest, Terry B Tuleu, Catherine Gul, Mine Orlu |
author_sort | Lopez, Felipe L |
collection | PubMed |
description | Introduction: Most conventional drug delivery systems are not acceptable for pediatric patients as they differ in their developmental status and dosing requirements from other subsets of the population. Technology platforms are required to aid the development of age-appropriate medicines to maximize patient acceptability while maintaining safety, efficacy, accessibility and affordability. Areas covered: The current approaches and novel developments in the field of age-appropriate drug delivery for pediatric patients are critically discussed including patient-centric formulations, administration devices and packaging systems. Expert opinion: Despite the incentives provided by recent regulatory modifications and the efforts of formulation scientists, there is still a need for implementation of pharmaceutical technologies that enable the manufacture of licensed age-appropriate formulations. Harmonization of endeavors from regulators, industry and academia by sharing learning associated with data obtained from pediatric investigation plans, product development pathways and scientific projects would be the way forward to speed up bench-to-market age appropriate formulation development. A collaborative approach will benefit not only pediatrics, but other patient populations such as geriatrics would also benefit from an accelerated patient-centric approach to drug delivery. |
format | Online Article Text |
id | pubmed-4673516 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2015 |
publisher | Informa Healthcare |
record_format | MEDLINE/PubMed |
spelling | pubmed-46735162015-12-15 Formulation approaches to pediatric oral drug delivery: benefits and limitations of current platforms Lopez, Felipe L Ernest, Terry B Tuleu, Catherine Gul, Mine Orlu Expert Opin Drug Deliv Reviews Introduction: Most conventional drug delivery systems are not acceptable for pediatric patients as they differ in their developmental status and dosing requirements from other subsets of the population. Technology platforms are required to aid the development of age-appropriate medicines to maximize patient acceptability while maintaining safety, efficacy, accessibility and affordability. Areas covered: The current approaches and novel developments in the field of age-appropriate drug delivery for pediatric patients are critically discussed including patient-centric formulations, administration devices and packaging systems. Expert opinion: Despite the incentives provided by recent regulatory modifications and the efforts of formulation scientists, there is still a need for implementation of pharmaceutical technologies that enable the manufacture of licensed age-appropriate formulations. Harmonization of endeavors from regulators, industry and academia by sharing learning associated with data obtained from pediatric investigation plans, product development pathways and scientific projects would be the way forward to speed up bench-to-market age appropriate formulation development. A collaborative approach will benefit not only pediatrics, but other patient populations such as geriatrics would also benefit from an accelerated patient-centric approach to drug delivery. Informa Healthcare 2015-11-02 2015-07-13 /pmc/articles/PMC4673516/ /pubmed/26165848 http://dx.doi.org/10.1517/17425247.2015.1060218 Text en © 2015 The Author(s). Published by Taylor & Francis. http://creativecommons.org/licenses/by/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Reviews Lopez, Felipe L Ernest, Terry B Tuleu, Catherine Gul, Mine Orlu Formulation approaches to pediatric oral drug delivery: benefits and limitations of current platforms |
title | Formulation approaches to pediatric oral drug delivery: benefits and limitations of current platforms |
title_full | Formulation approaches to pediatric oral drug delivery: benefits and limitations of current platforms |
title_fullStr | Formulation approaches to pediatric oral drug delivery: benefits and limitations of current platforms |
title_full_unstemmed | Formulation approaches to pediatric oral drug delivery: benefits and limitations of current platforms |
title_short | Formulation approaches to pediatric oral drug delivery: benefits and limitations of current platforms |
title_sort | formulation approaches to pediatric oral drug delivery: benefits and limitations of current platforms |
topic | Reviews |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4673516/ https://www.ncbi.nlm.nih.gov/pubmed/26165848 http://dx.doi.org/10.1517/17425247.2015.1060218 |
work_keys_str_mv | AT lopezfelipel formulationapproachestopediatricoraldrugdeliverybenefitsandlimitationsofcurrentplatforms AT ernestterryb formulationapproachestopediatricoraldrugdeliverybenefitsandlimitationsofcurrentplatforms AT tuleucatherine formulationapproachestopediatricoraldrugdeliverybenefitsandlimitationsofcurrentplatforms AT gulmineorlu formulationapproachestopediatricoraldrugdeliverybenefitsandlimitationsofcurrentplatforms |